NCT00632216

A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis

Multicenter and Prospective Study to Determine the Satisfaction With Actonel (Risedronate Sodium) 35mg Once a Week Using Biochemical Markers of Bone as a Control, in Postmenopausal Women With Osteoporosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 464 (actual)
• Sponsor: Sanofi · Industry
• Sex: Female
• Age: 55 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study in the labeled and real conditions of prescription of Actonel will investigate the satisfaction of patients with its new formulation: 35 mg Once A Week. The study will also measure response rates in CTX (the C-telopeptide of type I collagen) at baseline and after 12 weeks of treatment with risedronate 35 mg Once A Week.

Conditions

• Osteoporosis, Postmenopausal

Interventions

Type	Name	Description
DRUG	Risedronate Sodium

Timeline

• Start date: 2004-05-01
• Completion: 2006-05-01
• First posted: 2008-03-10
• Last updated: 2008-03-11